Literature DB >> 11890651

Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines.

P Greenberg1.   

Abstract

Results of these trials provide evidence for biological activity and some clinical efficacy of agents potentially blocking inhibitory cytokines in patients with MDS. However, given the limited responses, it appears that factors additional to TNFalpha inhibitory activity contribute to the development of cytopenias in these patients. Further studies are warranted using anti-TNFalpha/anti-inhibitory cytokine approaches, either alone or in combination with other agents, capable of abrogating the effects of additional inhibitory mechanisms in MDS.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11890651      PMCID： PMC1766670          DOI： 10.1136/ard.60.90003.iii41

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  11 in total

1.  Apoptosis in refractory anaemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases.

Authors:  E Hellström-Lindberg; J Schmidt-Mende; A M Forsblom; B Christensson; B Fadeel; B Zhivotovsky
Journal:  Br J Haematol       Date:  2001-03       Impact factor: 6.998

2.  The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.

Authors:  J E Parker; G J Mufti; F Rasool; A Mijovic; S Devereux; A Pagliuca
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes.

Authors:  A Ali; S D Mundle; D Ragasa; S Reza; V Shetty; B Y Mativi; J D Cartlidge; M Azharuddin; H Qawi; S Dar; A Raza
Journal:  J Hematother Stem Cell Res       Date:  1999-08

4.  Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.

Authors:  K Shimazaki; K Ohshima; J Suzumiya; C Kawasaki; M Kikuchi
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

5.  Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.

Authors:  D Bouscary; J De Vos; M Guesnu; K Jondeau; F Viguier; J Melle; F Picard; F Dreyfus; M Fontenay-Roupie
Journal:  Leukemia       Date:  1997-06       Impact factor: 11.528

6.  Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes.

Authors:  V Shetty; S Mundle; S Alvi; M Showel; L Broady-Robinson; S Dar; R Borok; J Showel; S Gregory; S Rifkin; S Gezer; A Parcharidou; P Venugopal; R Shah; B Hernandez; M Klein; D Alston; E Robin; C Dominquez; A Raza
Journal:  Leuk Res       Date:  1996 Nov-Dec       Impact factor: 3.156

7.  Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome.

Authors:  H J Deeg; C Beckham; M R Loken; E Bryant; M Lesnikova; H M Shulman; T Gooley
Journal:  Leuk Lymphoma       Date:  2000-04

8.  Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells.

Authors:  R Rajapaksa; N Ginzton; L S Rott; P L Greenberg
Journal:  Blood       Date:  1996-12-01       Impact factor: 22.113

9.  A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome.

Authors:  G M Gersuk; C Beckham; M R Loken; P Kiener; J E Anderson; A Farrand; A B Troutt; J A Ledbetter; H J Deeg
Journal:  Br J Haematol       Date:  1998-10       Impact factor: 6.998

Review 10.  Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment.

Authors:  P L Greenberg
Journal:  Leuk Res       Date:  1998-12       Impact factor: 3.156
View more
  3 in total

1.  Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

Authors:  Tony A Navas; Mani Mohindru; Myka Estes; Jing Ying Ma; Lubomir Sokol; Perry Pahanish; Simrit Parmar; Edwin Haghnazari; Li Zhou; Robert Collins; Irene Kerr; Aaron N Nguyen; Yin Xu; Leonidas C Platanias; Alan A List; Linda S Higgins; Amit Verma
Journal:  Blood       Date:  2006-08-29       Impact factor: 22.113

Review 2.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

Review 3.  Signal transduction inhibitors in treatment of myelodysplastic syndromes.

Authors:  Lohith Bachegowda; Oleg Gligich; Ionnis Mantzaris; Carolina Schinke; Dale Wyville; Tatiana Carrillo; Ira Braunschweig; Ulrich Steidl; Amit Verma
Journal:  J Hematol Oncol       Date:  2013-07-10       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.